What is Kallyope?
Headquartered at the Alexandria Center for Life Science in New York City, Kallyope operates at the intersection of advanced technology and molecular biology. The company utilizes a cross-disciplinary approach, integrating sequencing, bioinformatics, and neural imaging to decode the complex biology of the gut-brain axis. By mapping these biological pathways, Kallyope aims to develop novel therapeutics that address significant unmet medical needs. Its market position is bolstered by a robust ecosystem of scientific partners and a commitment to data-driven drug discovery, positioning it as a leader in the next generation of precision medicine.
How much funding has Kallyope raised?
Kallyope has raised a total of $486.1M across 5 funding rounds:
Private Equity
$28.1M
Series A
$44M
Series B
$66M
Series C
$112M
Series D
$236M
Private Equity (2015): $28.1M, investors not publicly disclosed
Series A (2015): $44M led by Lux Capital, Illumina Inc, Polaris Partners, The Column Group, and Alexandria Venture
Series B (2018): $66M supported by Two Sigma Ventures, Illumina Ventures, Polaris Partners, Alexandria, EUCLIDEAN CAPITAL, Lux Capital, and The Column Group
Series C (2020): $112M featuring Lux Capital, Euclidean Capital, Polaris Partners, The Column Group, Casdin Capital , LLC, Greenspring Associates Inc, Two Sigma Ventures, Illumina Ventures, Alexandria Venture Investments, and Bill Gates
Series D (2022): $236M backed by Mubadala and The Column Group
Key Investors in Kallyope
The Column Group
A venture ecosystem focused on advancing scientific innovation in the life sciences sector, providing comprehensive support from inception to exit.
Lux Capital
A New York-based venture capital firm that invests in early-stage and growth-stage companies at the intersection of science and technology.
Polaris Partners
A venture capital firm specializing in backing transformational companies in the biotech and healthcare sectors with over two decades of experience.
What's next for Kallyope?
Following the latest capital infusion, Kallyope is well-positioned to accelerate its clinical development programs and expand its proprietary technology platform. The company's strategic roadmap focuses on translating its deep biological insights into tangible therapeutic candidates. As it scales, Kallyope will likely prioritize the advancement of its lead assets through clinical trials while continuing to leverage its unique interdisciplinary research model. The sustained interest from top-tier venture firms and strategic investors suggests a clear trajectory toward long-term commercialization and potential industry-defining breakthroughs in the life sciences sector.
See full Kallyope company page
